SEC Form SC 13D/A filed by Lantern Pharma Inc. (Amendment)

SEC Form SC 13D/A filed by Lantern Pharma Inc. (Amendment)

Recent Analyst Ratings for
$LTRN

$LTRN
Insider Trading

$LTRN
Press Releases

$LTRN
SEC Filings

$LTRN
Financials

$LTRN
Leadership Updates

$LTRN
Large Ownership Changes

Chat with this insight

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Keyser D Jeffrey exercised 3,832 in-the-money shares at a strike of $3.13 (SEC Form 4)

SEC Form 4 filed by Director Keyser D Jeffrey

SEC Form 4 filed by Director Maccecchini Maria-Luisa

Fastest customizable press release news feed in the world

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

Lantern Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by Lantern Pharma Inc.

Lantern Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Live finance-specific insights

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates

Live Leadership Updates

Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives

This live feed shows all institutional transactions in real time.

3/1/24 4:10:40 PM ET

$LTRN

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $LTRN alert in real time by email

SC 13D/A 1 tm247761d1_sc13da.htm SC 13D/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

Lantern Pharma Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

51654W101

(CUSIP Number)

Bios Equity Partners, LP

1751 River Run, Suite 400

Fort Worth, Texas

Tel: (817) 984-9197

With a Copy to:

Rick Jordan

Polsinelli PC

2950 Harwood St., Suite 2100

Dallas, Texas 75201

Tel: (214) 397-0030

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

February 28, 2024

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ¨

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 51654W101

1		NAME OF REPORTING PERSONS BIOS FUND I, LP
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3		SEC USE ONLY
4		SOURCE OF FUNDS WC
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ¨
6		CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE, UNITED STATES

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER -0-
	8	SHARED VOTING POWER 371,950 (1)
	9	SOLE DISPOSITIVE POWER -0-
	10	SHARED DISPOSITIVE POWER 371,950 (1)

11		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 371,950 (1)
12		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
13		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 3.5% (2)
14		TYPE OF REPORTING PERSON PN

(1)

Consists of 371,950 shares of common stock of the Issuer, par value $0.0001 per share (“Shares”) directly held by Bios Fund I, LP (“Bios Fund I”) as of the date hereof.

(2)

Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP, LP (“Bios Fund I QP”) on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, LP (“Bios Fund II”), Bios Fund II QP, LP (“Bios Fund II QP”) and Bios Fund II NT, LP (“Bios Fund II NT”) on January 17, 2024.

CUSIP No. 51654W101

1		NAME OF REPORTING PERSONS BIOS FUND I QP, LP
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3		SEC USE ONLY
4		SOURCE OF FUNDS WC
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ¨
6		CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE, UNITED STATES

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER -0-
	8	SHARED VOTING POWER 217,553 (1)
	9	SOLE DISPOSITIVE POWER -0-
	10	SHARED DISPOSITIVE POWER 217,553 (1)

11		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 217,553 (1)
12		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
13		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 2.0% (2)
14		TYPE OF REPORTING PERSON PN

(1)

Consists of 217,553 Shares directly held by Bios Fund I QP as of the date hereof.

(2)

Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

CUSIP No. 51654W101

1		NAME OF REPORTING PERSONS BIOS FUND II, LP
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3		SEC USE ONLY
4		SOURCE OF FUNDS WC
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ¨

CITIZENSHIP OR PLACE OF ORGANIZATION

DELAWARE, UNITED STATES

(1)

Consists of 137,832 Shares directly held by Bios Fund II as of the date hereof.

(2)

Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

CUSIP No. 51654W101

NAME OF REPORTING PERSONS

BIOS FUND II QP, LP

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨ (b) x

3		SEC USE ONLY
4		SOURCE OF FUNDS WC
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ☐
6		CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE, UNITED STATES

(1)

Consists of 450,118 Shares directly held by Bios Fund II QP as of the date hereof.

(2)

Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

CUSIP No. 51654W101


1		NAME OF REPORTING PERSONS BIOS FUND II NT, LP
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3		SEC USE ONLY
4		SOURCE OF FUNDS WC
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ¨
6		CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE, UNITED STATES

(1)

Consists of 60,256 Shares directly held by Bios Fund II NT as of the date hereof.

(2)

Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

CUSIP No. 51654W101


1		NAME OF REPORTING PERSONS BP DIRECTORS, LP
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3		SEC USE ONLY
4		SOURCE OF FUNDS OO
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ¨
6		CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE, UNITED STATES

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

26,093 (1)

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

0.2% (2)

TYPE OF REPORTING PERSON

(1)

Consists of 26,093 Shares directly held by BP Directors, LP (“Bios Directors”) as of the date hereof.

(2)

Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

CUSIP No. 51654W101


1		NAME OF REPORTING PERSONS BIOS EQUITY PARTNERS, LP
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3		SEC USE ONLY
4		SOURCE OF FUNDS AF
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ¨
6		CITIZENSHIP OR PLACE OF ORGANIZATION TEXAS, UNITED STATES

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER -0-
	8	SHARED VOTING POWER 615,596 (1)
	9	SOLE DISPOSITIVE POWER -0-
	10	SHARED DISPOSITIVE POWER 615,596 (1)

(1)

Consists of (i) 371,950 Shares directly held by Bios Fund I, (ii) 217,553 Shares directly held by Bios Fund I QP and (iii) 26,093 Shares directly held by Bios Directors, in each case, as of the date hereof. Bios Equity Partners, LP (“Bios Equity I”) is the general partner of Bios Fund I, Bios Fund I QP and Bios Directors. In its capacity as the general partner of these entities, Bios Equity I may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by these entities.

(2)

Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

CUSIP No. 51654W101

NAME OF REPORTING PERSONS

BIOS EQUITY PARTNERS II, LP

2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3		SEC USE ONLY
4		SOURCE OF FUNDS AF
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ¨
6		CITIZENSHIP OR PLACE OF ORGANIZATION TEXAS, UNITED STATES

(1)

Consists of (i) 137,832 Shares directly held by Bios Fund II, (ii) 450,118 Shares directly held by Bios Fund II QP and (iii) 60,256 Shares directly held by Bios Fund II NT, in each case, as of the date hereof. Bios Equity Partners II, LP (“Bios Equity II”) is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. In its capacity as the general partner of these entities, Bios Equity II may be deemed to have shared voting and/or dispositive power with respect to Shares and warrants to purchase Shares, in each case, directly held by these entities.

(2)

Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

CUSIP No. 51654W101


1		NAME OF REPORTING PERSONS CAVU MANAGEMENT, LP
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3		SEC USE ONLY
4		SOURCE OF FUNDS AF
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ¨
6		CITIZENSHIP OR PLACE OF ORGANIZATION TEXAS, UNITED STATES

(1)

Consists of (i) 371,950 Shares directly held by Bios Fund I, (ii) 217,553 Shares directly held by Bios Fund I QP, (iii) 137,832 Shares directly held by Bios Fund II, (iv) 450,118 Shares directly held by Bios Fund II QP, (v) 60,256 Shares directly held by Bios Fund II NT and (vi) 26,093 Shares held by Bios Directors, in each case, as of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and Bios Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP (“Cavu Management”) is a general partner of Bios Equity I and Bios Equity II. In its capacity as a general partner of Bios Equity I and Bios Equity II, Cavu Management may be deemed to have shared voting and/or dispositive power with respect to Shares and warrants to purchase Shares, in each case, directly or indirectly held by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT and Bios Directors.

(2)

Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

CUSIP No. 51654W101

SOURCE OF FUNDS

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

CITIZENSHIP OR PLACE OF ORGANIZATION

TEXAS, UNITED STATES

(1)

Consists of (i) 371,950 Shares directly held by Bios Fund I, (ii) 217,553 Shares directly held by Bios Fund I QP, (iii) 137,832 Shares directly held by Bios Fund II, (iv) 450,118 Shares directly held by Bios Fund II QP, (v) 60,256 Shares directly held by Bios Fund II NT and (vi) 26,093 Shares held by Bios Directors, in each case, as of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and Bios Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Capital Management, LP (“Bios Management”) is a general partner of Bios Equity I and Bios Equity II. In its capacity as a general partner of Bios Equity I and Bios Equity II, Bios Management may be deemed to have shared voting and/or dispositive power with respect to Shares and warrants to purchase Shares, in each case, directly or indirectly held by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT and Bios Directors.

(2)

Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

CUSIP No. 51654W101


1		NAME OF REPORTING PERSONS CAVU ADVISORS, LLC
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3		SEC USE ONLY
4		SOURCE OF FUNDS AF
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ¨
6		CITIZENSHIP OR PLACE OF ORGANIZATION TEXAS, UNITED STATES

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER -0-
	8	SHARED VOTING POWER 1,263,802 (1)
	9	SOLE DISPOSITIVE POWER -0-
	10	SHARED DISPOSITIVE POWER 1,263,802 (1)

(1)

Consists of (i) 371,950 Shares directly held by Bios Fund I, (ii) 217,553 Shares directly held by Bios Fund I QP, (iii) 137,832 Shares directly held by Bios Fund II, (iv) 450,118 Shares directly held by Bios Fund II QP, (v) 60,256 Shares directly held by Bios Fund II NT and (vi) 26,093 Shares held by Bios Directors, in each case, as of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and Bios Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management is a general partner of Bios Equity I and Bios Equity II. Cavu Advisors, LLC (“Cavu Advisors”) is the general partner of Cavu Management, and therefore, may be deemed to have shared voting and/or dispositive power with respect to Shares and warrants to purchase Shares, in each case, directly or indirectly held by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT and Bios Directors.

(2)

Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

CUSIP No. 51654W101

1		NAME OF REPORTING PERSONS BIOS ADVISORS GP, LLC
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3		SEC USE ONLY
4		SOURCE OF FUNDS AF
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ¨
6		CITIZENSHIP OR PLACE OF ORGANIZATION TEXAS, UNITED STATES

(1)

Consists of (i) 371,950 Shares directly held by Bios Fund I, (ii) 217,553 Shares directly held by Bios Fund I QP, (iii) 137,832 Shares directly held by Bios Fund II, (iv) 450,118 Shares directly held by Bios Fund II QP, (v) 60,256 Shares directly held by Bios Fund II NT and (vi) 26,093 Shares held by Bios Directors, in each case, as of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and Bios Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors GP, LLC (“Bios Advisors”) is the general partner of Bios Management, and therefore, may be deemed to have shared voting and/or dispositive power with respect to Shares and warrants to purchase Shares, in each case, directly or indirectly held by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT and Bios Directors.

(2)

Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

CUSIP No. 51654W101


1		NAME OF REPORTING PERSONS LESLIE WAYNE KREIS, JR.
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3		SEC USE ONLY
4		SOURCE OF FUNDS AF, OO
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ¨
6		CITIZENSHIP OR PLACE OF ORGANIZATION UNITED STATES

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 0
	8	SHARED VOTING POWER 1,263,802 (1)
	9	SOLE DISPOSITIVE POWER 0
	10	SHARED DISPOSITIVE POWER 1,263,802 (1)

(1)

Consists of (i) 371,950 Shares directly held by Bios Fund I, (ii) 217,553 Shares directly held by Bios Fund I QP, (iii) 137,832 Shares directly held by Bios Fund II, (iv) 450,118 Shares directly held by Bios Fund II QP, (v) 60,256 Shares directly held by Bios Fund II NT and (vi) 26,093 Shares held by Bios Directors, in each case, as of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and Bios Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management is a general partner of Bios Equity I and Bios Equity II. Cavu Advisors, an entity controlled by Mr. Kreis, is the general partner of Cavu Management. As the manager of Cavu Advisors, Mr. Kreis may be deemed to have shared voting and/or dispositive power with respect to Shares and warrants to purchase Shares, in each case, directly or indirectly held by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT and Bios Directors.

(2)

Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

CUSIP No. 51654W101

1		NAME OF REPORTING PERSONS AARON GLENN LOUIS FLETCHER
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3		SEC USE ONLY
4		SOURCE OF FUNDS AF
5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) ¨
6		CITIZENSHIP OR PLACE OF ORGANIZATION UNITED STATES

(1)

Consists of (i) 371,950 Shares directly held by Bios Fund I, (ii) 217,553 Shares directly held by Bios Fund I QP, (iii) 137,832 Shares directly held by Bios Fund II, (iv) 450,118 Shares directly held by Bios Fund II QP, (v) 60,256 Shares directly held by Bios Fund II NT and (vi) 26,093 Shares held by Bios Directors, in each case, as of the date hereof. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and Bios Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors, an entity controlled by Aaron Glenn Louis Fletcher, is the general partner of Bios Management. As the manager of Bios Advisors, Mr. Fletcher may be deemed to have shared voting and/or dispositive power with respect to Shares and warrants to purchase Shares, in each case, directly or indirectly held by Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT and Bios Directors.

(2)

Based on 10,743,824 Shares, which consists of (i) 10,869,040 Shares as of November 3, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, minus (ii) 145,348 Shares purchased in the aggregate by the Issuer from Bios Fund I and Bios Fund I QP on November 21, 2023, plus (iii) 20,132 Shares issued in the aggregate upon the cashless exercise of warrants directly held by Bios Fund II, Bios Fund II QP and Bios Fund II NT on January 17, 2024.

Item 1.

SECURITY AND ISSUER

This Amendment No. 3 hereby amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission on June 15, 2020 (the “Original Schedule 13D”), as amended by the statement on Schedule 13D/A filed with the Securities and Exchange Commission on March 22, 2022 (“Amendment No. 1”), as further amended by the statement on Schedule 13D/A filed with the Securities and Exchange Commission on December 1, 2023 (“Amendment No. 2” and, together with the Original Schedule 13D and Amendment No. 1, the “Prior Statements”). The securities to which the Schedule 13D relates are the shares of common stock, par value $0.0001 per share (the “Shares”), of Lantern Pharma, Inc., a Delaware corporation (the “Issuer”).

The Purpose of this Amendment No. 3 is to disclose the sale of Shares by each of Bios Fund II, LP (“Bios Fund II”), Bios Fund II QP, LP (“Bios Fund II QP”) and Bios Fund II NT, LP (“Bios Fund II NT”) on the open market. Except as otherwise provided herein, each Item of the Prior Statements remains unchanged. Capitalized terms used herein but not defined in this Amendment No. 3 shall have the meaning ascribed to such term in the Prior Statements.

Item 5.

INTEREST IN SECURITIES OF THE ISSUER

Item 5 of the Schedule 13D is hereby amended and restated in its entirety to read as follows:

(a)	See rows (11) and (13) of the cover pages to this Amendment No. 3 for the aggregate number of Shares and percentages of the Shares beneficially owned by each of the Reporting Persons. See footnotes (1) and (2), as applicable, of the cover pages to this Amendment No. 3 for the calculations used in determining the percentages of Shares beneficially owned by each of the Reporting Persons.

(b)	See rows (7) through (10) of the cover pages to this Amendment No. 3 for the number of Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

(c)	On January 17, 2024, each of Bios Fund II NT, Bios Fund II QP and Bios Fund II exercised warrants to purchase 7,347, 54,873 and 16,801, respectively, shares of common stock of the Issuer. Each of Bios Fund II NT, Bios Fund II QP and Bios Fund II paid the exercise price on a cashless basis, resulting in the Issuer withholding 5,475, 40,893 and 12,521, respectively, of the warrant shares to pay the exercise price and issuing Bios Fund II NT, Bios Fund II QP and Bios Fund II the remaining 1,872, 13,980 and 4,280 shares respectively. On February 27, 2024, each of Bios Fund II NT, Bios Fund II QP and Bios Fund II sold 4,649, 34,371 and 10,620, respectively, shares of common stock of the Issuer on the open market at a weighted average price of $4.40. These shares were sold in multiple transactions ranging from $4.35 to $4.50. The Reporting Persons undertake to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. On February 28, 2024, each of Bios Fund II NT, Bios Fund II QP and Bios Fund II sold 6,909, 51,608 and 15,780, respectively, shares of common stock of the Issuer on the open market at a weighted average price of $4.85. These shares were sold in multiple transactions ranging from $4.60 to $5.21. The Reporting Persons undertake to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request. On February 29, 2024, each of Bios Fund II NT, Bios Fund II QP and Bios Fund II sold 1,832, 13,686 and 4,185, respectively, shares of common stock of the Issuer on the open market at a weighted average price of $4.87. These shares were sold in multiple transactions ranging from $4.62 to $5.33. The Reporting Persons undertake to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

(d)	Except as described in this Amendment No. 3 to the knowledge of the Reporting Persons, only the reporting Persons have the right to receive or the power to direct receipt of dividends from, or proceeds from the sale of, the Shares reported by the Schedule 13D.

(e)	Not applicable.

Item 7.	EXHIBITS

A	Joint Filing Agreement, dated June 23, 2020 (incorporated by reference to the Original Schedule 13D, filed on June 23, 2020).

SIGNATURES

After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: March 1, 2024

BIOS FUND I, LP

By:	Bios Equity Partners, LP,
	its general partner

	By:	Cavu Management, LP,
		its general partner

		By:	Cavu Advisors, LLC,
			its general partner

			By:	/s/ Daniel Schwarz
				Daniel Schwarz
				Attorney-in-Fact

	By:	Bios Capital Management, LP,
		its general partner

		By:	Bios Advisors GP, LLC,
			its general partner

			By:	/s/ Daniel Schwarz
				Daniel Schwarz
				Attorney-in-Fact

BIOS FUND I QP, LP

By:	Bios Equity Partners, LP,
	its general partner

	By:	Cavu Management, LP,
		its general partner

		By:	Cavu Advisors, LLC,
			its general partner

			By:	/s/ Daniel Schwarz
				Daniel Schwarz
				Attorney-in-Fact

	By:	Bios Capital Management, LP,
		its general partner

		By:	Bios Advisors GP, LLC,
			its general partner

			By:	/s/ Daniel Schwarz
				Daniel Schwarz
				Attorney-in-Fact

BP DIRECTORS, LP

By:	Bios Equity Partners, LP,
	its general partner

	By:	Cavu Management, LP,
		its general partner

		By:	Cavu Advisors, LLC,
			its general partner

			By:	/s/ Daniel Schwarz
				Daniel Schwarz
				Attorney-in-Fact

	By:	Bios Capital Management, LP,
		its general partner

		By:	Bios Advisors GP, LLC,
			its general partner

			By:	/s/ Daniel Schwarz
				Daniel Schwarz
				Attorney-in-Fact

BIOS FUND II, LP

By:	Bios Equity Partners II, LP,
	its general partner

	By:	Cavu Management, LP,
		its general partner

		By:	Cavu Advisors, LLC,
			its general partner

			By:	/s/ Daniel Schwarz
				Daniel Schwarz
				Attorney-in-Fact

	By:	Bios Capital Management, LP,
		its general partner

		By:	Bios Advisors GP, LLC,
			its general partner

			By:	/s/ Daniel Schwarz
				Daniel Schwarz
				Attorney-in-Fact

BIOS FUND II QP, LP

By:	Bios Equity Partners II, LP,
	its general partner

	By:	Cavu Management, LP,
		its general partner

		By:	Cavu Advisors, LLC,
			its general partner

			By:	/s/ Daniel Schwarz
				Daniel Schwarz
				Attorney-in-Fact

	By:	Bios Capital Management, LP,
		its general partner

		By:	Bios Advisors GP, LLC,
			its general partner

			By:	/s/ Daniel Schwarz
				Daniel Schwarz
				Attorney-in-Fact

BIOS FUND II NT, LP

By:	Bios Equity Partners II, LP,
	its general partner

	By:	Cavu Management, LP,
		its general partner

		By:	Cavu Advisors, LLC,
			its general partner

			By:	/s/ Daniel Schwarz
				Daniel Schwarz
				Attorney-in-Fact

	By:	Bios Capital Management, LP,
		its general partner

		By:	Bios Advisors GP, LLC,
			its general partner

			By:	/s/ Daniel Schwarz
				Daniel Schwarz
				Attorney-in-Fact

BIOS EQUITY PARTNERS, LP

By:	Cavu Management, LP,
	its general partner

	By:	Cavu Advisors, LLC,
		its general partner

		By:	/s/ Daniel Schwarz
			Daniel Schwarz
			Attorney-in-Fact

By:	Bios Capital Management, LP,
	its general partner

	By:	Bios Advisors GP, LLC,
		its general partner

		By:	/s/ Daniel Schwarz
			Daniel Schwarz
			Attorney-in-Fact

BIOS EQUITY PARTNERS II, LP

By:	Cavu Management, LP,
	its general partner

	By:	Cavu Advisors, LLC,
		its general partner

		By:	/s/ Daniel Schwarz
			Daniel Schwarz
			Attorney-in-Fact

By:	Bios Capital Management, LP,
	its general partner

	By:	Bios Advisors GP, LLC,
		its general partner

		By:	/s/ Daniel Schwarz
			Daniel Schwarz
			Attorney-in-Fact

CAVU MANAGEMENT, LP

By:	Cavu Advisors, LLC,
	its general partner

	By:	/s/ Daniel Schwarz
		Daniel Schwarz
		Attorney-in-Fact


BIOS CAPITAL MANAGEMENT, LP

By:	Bios Advisors GP, LLC
	its general partner

	By:	/s/ Daniel Schwarz
		Daniel Schwarz
		Attorney-in-Fact

CAVU ADVISORS, LLC

By:	/s/ Daniel Schwarz
	Daniel Schwarz
	Attorney-in-Fact

BIOS ADVISORS GP, LLC

By:	/s/ Daniel Schwarz
	Daniel Schwarz
	Attorney-in-Fact

	/s/ Daniel Schwarz
	DANIEL SCHWARZ, as Attorney-in-Fact for Leslie Wayne Kreis, Jr.

	/s/ Daniel Schwarz
	DANIEL SCHWARZ, as Attorney-in-Fact for Aaron Glenn Louis Fletcher

Get the next $LTRN alert in real time by email

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

SOLE VOTING POWER

-0-

SHARED VOTING POWER

137,832 (1)

SOLE DISPOSITIVE POWER

-0-

SHARED DISPOSITIVE POWER

137,832 (1)